EUCTR2020-001173-69-DK进行中（未招募）1 期
Impact of LTBI treatment on glucose tolerance and chronic inflammation
Pernille Ravn0 个研究点目标入组 220 人开始时间: 2020年4月22日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •5: Inclusion and exclusion criteria:
- •5.a: Inclusion criteria group A
- •18+ years
- •Known DM type 2
- •5.b: Inclusion criteria group B
- •18+ years
- •LTBI positive
- •No diagnosis with or known DM (1 and 2)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 200
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •5.c: Exclusion criteria group A and B
- •Previous treatment for TB or LTBI
- •Known immunosuppression such as: HIV, steroid treatment within 14 days before inclusion, daily NSAID treatment, ongoing chemotherapy, ongoing immunomodulating treatment or splenectomy
- •Known contraindication to both RIF and INH
- •Known active liver disease
- •Known inflammatory or rheumatological diseases with immune activation such as IBD, RA, Psoriasis and Wegners granulomatosis
- •Recent antibiotic treatment (>2 days) or severe infection within 14 days before enrollment
- •Known active cancer
研究者
相似试验
已完成
4 期
Impact of LTBI Treatment on Glucose Tolerance and Chronic InflammationLatent TuberculosisDiabetes Mellitus, Type 2NCT04830462Herlev and Gentofte Hospital32
已完成
不适用
How sugars impact on lean and overweight/obese humansImpaired glucose toleranceNutritional, Metabolic, EndocrineISRCTN11113396niversity of Fribourg - Faculty of Science40
进行中（未招募）
1 期
The impact of liraglutide on glucose tolerance and the risk of type 2 diabetes in women with previous gestational diabetes mellitusGestational diabetes mellitus Non-alcoholic fatty liver diseaseMedDRA version: 20.0 Level: LLT Classification code 10018210 Term: Gestational diabetes mellitus System Organ Class: 100000004868MedDRA version: 20.1 Level: PT Classification code 10029530 Term: Non-alcoholic fatty liver System Organ Class: 10019805 - Hepatobiliary disordersEUCTR2012-001371-37-DKDr. med. Tina Vilsbøll160
已完成
不适用
A study in subjects with impaired glucose tolerance (IGT) to evaluate effects of AO-128 on prevention of type 2 diabetes mellitus (Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group comparison)Impaired glucose tolerance (IGT)JPRN-UMIN000001109Takeda Pharmaceutical Company Limited1,782
招募中
不适用
Investigation of impaired glucose tolerance using continuous glucose monitoring in patients with chronic heart failureChronic Heart FailureJPRN-UMIN000010263St. Marianna University School of Medicine200